Pemigatinib
Sign in to save this workspacePrimary targets: FGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
98.23
Gini
0.718
CATDS
0.022
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Pemigatinib. Strongest target: FGFR1 at 99.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FGFR1 | 99.9% | 0.1% |
| 2 | FGFR3 | 99.4% | 0.6% |
| 3 | FGFR2 | 98.7% | 1.3% |
| 4 | EIF2AK1 | 97.7% | 2.3% |
| 5 | FMS | 95.5% | 4.5% |
| 6 | FGFR4 | 93.9% | 6.1% |
| 7 | FLT4_VEGFR3 | 92.1% | 7.9% |
| 8 | EIF2AK2 | 85.3% | 14.7% |
| 9 | FLT1_VEGFR1 | 84.7% | 15.3% |
| 10 | MLK2_MAP3K10 | 81.3% | 18.7% |
| 11 | TAOK2_TAO1 | 80.3% | 19.7% |
| 12 | SIK3 | 79.4% | 20.6% |
| 13 | MST3_STK24 | 74.4% | 25.6% |
| 14 | STK25_YSK1 | 72.5% | 27.5% |
| 15 | GLK_MAP4K3 | 70.8% | 29.2% |
| 16 | MEKK2 | 67.2% | 32.8% |
| 17 | C_KIT | 65.4% | 34.6% |
| 18 | CDK6_CYCLIN_D3 | 63.3% | 36.7% |
| 19 | LYN | 61.7% | 38.3% |
| 20 | NEK1 | 59.0% | 41.0% |
Selectivity landscape
Where Pemigatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Pemigatinib.
Annotations
Sign in to read and post annotations.
Loading…